Hyundai Bioscience (CEO Sangki Oh) announced on the 7th that its Japanese joint venture 'VITABRID JAPAN' achieved sales of 8.4 billion yen (KRW 96 billion) in 2019, a 40% increase from the previous year.

Despite the COVID-19 pandemic that has swept the world, Vita Breed Japan has maintained a solid growth trend, recording sales of 9.3 billion won in March, up 9% from the previous year, and is expected to easily exceed its sales target of 120 billion won this year.

'Vitabreed Japan' is a local corporation established in 2014 as a joint investment between Hyundai Bio and Japan's largest marketing group, Vector. It is considered a leading player in the Japanese K-beauty cosmetics market by leading the vitamin C craze in the conservative Japanese cosmetics market.